While the U.S. gave Huawei a 90-day reprieve, allowing American businesses to keep selling specific products to the Chinese firm, it also added more affiliates of the...Technologyread more
United States Steel Corp will temporarily lay off hundreds of workers at its Great Lakes facility in Michigan in coming weeks, according to a filing the steelmaker made with...US Marketsread more
Home Depot shares, which are valued at $228.8 billion, are up more than 21% this year.Retailread more
The attacks come after state and local ransomware attacks in New York, Louisiana, Maryland and Florida resulted in the loss of significant sums.Technologyread more
U.K. Prime Minister Boris Johnson told the EU that a Brexit deal can still be approved by U.K. lawmakers if Brussels agrees to scrapping the contentious Irish "backstop."read more
Baidu posted better-than-expected earnings for the June quarter, swinging back to profit and managing to stabilize its core ad business.Technologyread more
Several big Pimco funds controlled by Ivascyn have reportedly been trimming their bond market positions in the U.K. and Europe.World Marketsread more
While Hong Kong leader Carrie Lam painted a bleak picture of the city's economy, she expressed hope that dialogue with protesters could provide "a way out."China Politicsread more
China's pursuit of the Middle East may spur growth in the Islamic finance sector.World Economyread more
Twitter and Facebook have suspended accounts believed to be tied to a state-backed disinformation campaign originating from inside China.Technologyread more
U.S. President Donald Trump and his former White House communications director Anthony Scaramucci have had a public falling out recently.Politicsread more
This stock had made sharp gains through the spring but then tumbled sharply into summer, before again ticking higher. Is Charles River Labs ready to run, again?
Charles River Labs has been a Jim Cramer favorite for almost two years now with the "Mad Money" host's optimism due, in part, to the company's business model. "Charles River provides universities and biopharmaceutical firms with everything they need to discover new drugs and they also conduct early stage clinical trials," Cramer explained.
Although long-term prospects sound positive, the price action earlier in the year was anything but.
As you can see from the chart, "From the first week of April through the first week of May, Charles River dropped from $61 down to $50, and it spent the next three months stuck in the low $50s, in part due to worries that drug companies were shifting their outsourced research budgets away from the early stage research that Charles River is all about and towards firms that specialize in later stage clinical trials," Cramer explained.
However, after talking with Jim Foster, the chairman and CEO of Charles River Laboratories, there's new reason to believe that business at his company is, again, on the upswing.
"We've got great demand in both big pharma and biotech," he said. "And we're getting full," Foster added, referring to the occupancy at facilities his company operates in which drugs are tested for safety and efficacy. "There had been a surplus of space but now it's filling up very nicely. The industry is at 70 percent and we're substantially higher than that."
Cramer thinks the renewed strength is reflected in .
"The company delivered a 15-cent earnings beat off of an 82-cent basis, with higher than expected revenues that rose 15.9 percent year over year, and management raised its full-year earnings guidance," he said. And sales growth exceeded 10 percent, Foster added.
Read more from Mad Money with Jim Cramer
Cramer: Companies trolling for takeover
Priceline lesson for Apple investors
The transforming MLP landscape
After talking with the CEO and sifting through earnings, Cramer thinks there's every reason for optimism.
"From what I'm hearing, it sounds like Charles River is back on track. Clients are spending again and (Foster says) the company is back on a sustained growth path. There's real need for what Charles River Labs does. I think the stock goes higher. "
Call Cramer: 1-800-743-CNBC
Questions for Cramer? email@example.com
Questions, comments, suggestions for the "Mad Money" website? firstname.lastname@example.org